- Previous Close
39.38 - Open
38.92 - Bid 39.21 x 308800
- Ask 39.24 x 40000
- Day's Range
38.92 - 39.47 - 52 Week Range
29.20 - 42.43 - Volume
267,954 - Avg. Volume
1,451,865 - Market Cap (intraday)
253.738B - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
20.55 - EPS (TTM)
1.91 - Earnings Date Jul 25, 2024
- Forward Dividend & Yield 1.35 (3.42%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
45.17
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
www.roche.com103,605
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
Recent News: RHHBY
View More
![[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months](https://s.yimg.com/uu/api/res/1.2/3tujng84jArYxPYsssA04w--~B/Zmk9ZmlsbDtoPTYzO3B5b2ZmPTA7dz04NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/84b0110bbf60eb8397db0461bc3549c4.cf.webp)
Performance Overview: RHHBY
Trailing total returns as of 2024-10-23, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RHHBY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RHHBY
View MoreValuation Measures
Market Cap
254.71B
Enterprise Value
284.33B
Trailing P/E
20.57
Forward P/E
13.32
PEG Ratio (5yr expected)
1.26
Price/Sales (ttm)
3.61
Price/Book (mrq)
7.50
Enterprise Value/Revenue
4.06
Enterprise Value/EBITDA
13.89
Financial Highlights
Profitability and Income Statement
Profit Margin
17.53%
Return on Assets (ttm)
12.49%
Return on Equity (ttm)
36.36%
Revenue (ttm)
60.58B
Net Income Avi to Common (ttm)
10.62B
Diluted EPS (ttm)
1.91
Balance Sheet and Cash Flow
Total Cash (mrq)
8.81B
Total Debt/Equity (mrq)
110.04%
Levered Free Cash Flow (ttm)
8.13B